Extracellular Release of HMGB1 as an Early Potential Biomarker for the Therapeutic Response in a Xenograft Model of Boron Neutron Capture Therapy

Extracellular Release of HMGB1 as an Early Potential Biomarker for the Therapeutic Response in a Xenograft Model of Boron Neutron Capture Therapy

Boron neutron capture therapy (BNCT) is a non-invasive therapeutic technique for treating malignant tumors, however, methods to evaluate its therapeutic efficacy and adverse reactions are lacking. High mobility group box 1 (HMGB1) is an inflammatory molecule released during cell death. Therefore, we...

Full description

Bibliographic Details
Main Authors: Shoji Imamichi, Lichao Chen, Tasuku Ito, Ying Tong, Takae Onodera, Yuka Sasaki, Satoshi Nakamura, PierLuigi Mauri, Yu Sanada, Hiroshi Igaki, Yasufumi Murakami, Minoru Suzuki, Jun Itami, Shinichiro Masunaga, Mitsuko Masutani
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Biology
Subjects:
<sup>10</sup>B-boronophenylalanine (BPA)
boron neutron capture therapy (BNCT)
boron neutron capture reaction (BNCR)
high mobility group box 1 (HMGB1)
Online Access:https://www.mdpi.com/2079-7737/11/3/420

Internet

https://www.mdpi.com/2079-7737/11/3/420

Similar Items